Quote of the Day

"All seem to be able to achieve the high bar of a mid to higher 90% cure rate. Anything short of this efficacy rate will make it hard for the product to compete in the market. By way of safety, all seem to have inherent safety profiles such that patients need to be monitored, but the majority seem to have manageable side effects on the whole."


— Lynn Nishida, area vice president of pharmacy at Solid Benefit Guidance, tells Specialty Pharmacy News about the eight next-generation therapies now available to treat hepatitis C.